Scholarlink

Background <p>Polygenic mutations play a significant role in the etiology of various growth-related disorders and bone deformities, influencing multiple physiological processes. Understanding the impact of polygenic mutations is crucial for the diagnosis, genetic counseling, and management of these complex conditions.</p> Case presentation <p>A boy first evaluated at 9 years and 10 months for short stature was diagnosed with compound heterozygous mutations in <i>PLEC</i>, <i>CD96</i>, and <i>RNU4ATAC</i> genes, with comorbid congenital multiple epiphyseal dysplasia and growth hormone deficiency. These mutations collectively contributed to severe short stature, skeletal deformities, and delayed neurodevelopment. Orthopedic surgeries were performed at 9 years and 10 months (first intervention), 11 years and 6 months (second intervention), and 12 years and 9 months (third intervention), while growth hormone therapy (GHT) was initiated at 11 years and 10 months. Over 25 months of GHT, his height increased by 18&#xa0;cm, bone age advanced by five years, and gait improved. Final clinical evaluation at 13 years and 11 months confirmed sustained improvements in height (137&#xa0;cm) and motor function.</p> Conclusion <p>This case involves a child with short stature caused by rare mutations of <i>PLEC</i>, <i>CD96</i>, and <i>RNU4ATAC</i>. This is the first case report documenting the concurrent presence of all three rare mutations. Orthopedic surgery and GHT were employed to improve the patient’s development and quality of life. We propose that early identification of high-risk factors, genetic screening, and comprehensive treatment can enhance therapeutic effectiveness and improve the patient’s quality of life.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Concurrent mutations in RNU4ATAC, PLEC, and CD96 in a child with severe short stature and skeletal dysplasia: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月15日

查看全文
  • Hui Wang,
  • Jinhui Wang,
  • Darong Chen

摘要

Background

Polygenic mutations play a significant role in the etiology of various growth-related disorders and bone deformities, influencing multiple physiological processes. Understanding the impact of polygenic mutations is crucial for the diagnosis, genetic counseling, and management of these complex conditions.

Case presentation

A boy first evaluated at 9 years and 10 months for short stature was diagnosed with compound heterozygous mutations in PLEC, CD96, and RNU4ATAC genes, with comorbid congenital multiple epiphyseal dysplasia and growth hormone deficiency. These mutations collectively contributed to severe short stature, skeletal deformities, and delayed neurodevelopment. Orthopedic surgeries were performed at 9 years and 10 months (first intervention), 11 years and 6 months (second intervention), and 12 years and 9 months (third intervention), while growth hormone therapy (GHT) was initiated at 11 years and 10 months. Over 25 months of GHT, his height increased by 18 cm, bone age advanced by five years, and gait improved. Final clinical evaluation at 13 years and 11 months confirmed sustained improvements in height (137 cm) and motor function.

Conclusion

This case involves a child with short stature caused by rare mutations of PLEC, CD96, and RNU4ATAC. This is the first case report documenting the concurrent presence of all three rare mutations. Orthopedic surgery and GHT were employed to improve the patient’s development and quality of life. We propose that early identification of high-risk factors, genetic screening, and comprehensive treatment can enhance therapeutic effectiveness and improve the patient’s quality of life.